Pentixapharm Holding AG (ETR:PTP) | Finanzwire

Basculer en Français

11218	Companies
248750	Keywords
176522	Articles
134579	Press releases

Headlines Articles Press releases Pentixapharm Holding AG

Home
Companies
Pentixapharm Holding AG

BRIEF

published on 10/19/2026 at 22:21, 3 days ago

Pentixapharm Holding AG Adjusts 2026 Earnings Forecast Amid PANDA Study Timeline Change

Financial Outlook Guidance Revision 2026 Earnings PANDA Phase 3 Cost Deferral
PRESS RELEASE

published on 10/19/2026 at 22:16, 3 days ago

EQS-Adhoc: Pentixapharm Holding AG: 2026 Earnings Guidance Raised; First-Patient Enrollment in PANDA Phase 3 Study Now Expected in the First Quarter of 2027
Pentixapharm Holding AG raises 2026 earnings guidance, expects first-patient enrollment in PANDA Phase 3 study by Q1 2027, with reduced net loss and extended cash runway

Net Loss Earnings Guidance Cash Runway Pentixapharm Holding AG PANDA Phase 3 Study
BRIEF

published on 10/19/2026 at 08:35, 3 days 13 hours ago

Pentixapharm Advances Phase 3 PANDA Study in Primary Aldosteronism

FDA Fast Track Primary Aldosteronism Phase 3 PANDA Non-invasive Diagnosis Pentixafor PET
PRESS RELEASE

published on 10/19/2026 at 08:30, 3 days 14 hours ago

Pentixapharm Highlights Growing International Evidence Supporting Phase 3 PANDA Study in Primary Aldosteronism at EANM 2026
Pentixapharm highlights international evidence supporting Phase 3 PANDA study at EANM 2026, targeting primary aldosteronism with Pentixafor PET imaging

Pentixapharm Primary Aldosteronism CXCR4 Phase 3 PANDA EANM 2026
BRIEF

published on 10/02/2026 at 20:28, 20 days 2 hours ago

Bafin Identifies Errors in Pentixapharm Holding AG's 2024 Financial Statements

Financial Reporting Pentixapharm Holding AG Intangible Assets BaFin Review Capital Reserve
PRESS RELEASE

published on 10/02/2026 at 20:23, 20 days 2 hours ago

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Bafin concludes review of Pentixapharm Holding AG's 2024 financial statements, finding errors. No material impact expected on business. Legal remedies not sought

Financial Reporting 2024 BaFin Pentixapharm Holding AG Error Finding
BRIEF

published on 08/06/2026 at 08:05, 2 months 16 days ago

Pentixapharm Reports Q2 and H1 2026 Results and Advances Phase 3 Program

Financial Results Oncology Pipeline FDA Fast Track Pentixapharm Phase 3 PANDA
PRESS RELEASE

published on 08/06/2026 at 08:00, 2 months 16 days ago

Pentixapharm Reports Second Quarter and First Half 2026 Results and Advances Phase 3 Panda Program
Pentixapharm Holding AG reports financial results for second quarter and first half of 2026, advancing Phase 3 Panda Program in oncology and cardiovascular sectors

Financial Results Oncology Phase 3 Pentixapharm PANDA Program
BRIEF

published on 07/31/2026 at 09:05, 2 months 22 days ago

Pentixapharm Holding AG Advances with PentixaFor in Phase 3

Capital Raise Phase 3 PentixaFor Radiopharma PANDA Study
PRESS RELEASE

published on 07/31/2026 at 09:00, 2 months 22 days ago

Original-Research: Pentixapharm Holding AG (von NuWays AG): BUY
Research update: Pentixapharm Holding AG positioned for Phase 3 with strong financing secured for PentixaFor diagnostic agent. Potential commercial partnering in 2027. Target price EUR 7.20

Financing Phase 3 Pentixapharm Commercial Partnering Diagnostic Agent

Accesswire

Published on 10/22/2026 at 16:00, 6 hours 30 minutes ago

Future Fuels Announces Closing of Brokered Offering for Gross Proceeds of C$6.6 Million
Published on 10/22/2026 at 14:30, 8 hours ago

Unusual Machines Receives $16.9 Million Purchase Order from Powerus for American-Made Drone Components
Published on 10/22/2026 at 14:00, 8 hours 30 minutes ago

Jericho Energy Ventures Amends Investor Relations Agreement with Orange Group Advisors
Published on 10/22/2026 at 14:00, 8 hours 30 minutes ago

Viemed Healthcare Announces Third Quarter 2026 Earnings Conference Call Details
Published on 10/22/2026 at 13:45, 8 hours 45 minutes ago

Karbon-X (OTCQB:KARX) Accelerates High-Margin Transformation in Q1 FY2027: Gross Margin Expands to 32%, Operating Cash Burn Drops 55%, and Deferred Revenue Reaches $4.3 Million

View all ACCESSWIRE

EQS Group

Published on 10/22/2026 at 22:10, 20 minutes ago

Quantinuum to Report Third Quarter Financial Results on November 5, 2026
Published on 10/22/2026 at 20:00, 2 hours 30 minutes ago

Exchange offer for Eleving Group 2023/2028 bonds (ISIN DE000A3LL7M4) completed
Published on 10/22/2026 at 18:45, 3 hours 45 minutes ago

Swedish Export Credit Corporation (SEK): Europe's defence build-up opens opportunities for Swedish companies in Germany
Published on 10/22/2026 at 18:12, 4 hours 18 minutes ago

LION E-Mobility AG: CEO Dr. Joachim Damasky to retire at the end of January 2027
Published on 10/22/2026 at 18:10, 4 hours 20 minutes ago

EQS-Adhoc: LION E-Mobility AG: CEO Dr. Joachim Damasky to retire at the end of January 2027

Les Echos

Published on 10/22/2026 at 18:00, 4 hours 30 minutes ago

THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 4 hours 30 minutes ago

bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Published on 10/22/2026 at 18:00, 4 hours 30 minutes ago

H1 2026: marked improvement in operating results
Published on 10/22/2026 at 17:47, 4 hours 43 minutes ago

Aéroports de Paris SA - 2026 9-month revenue
Published on 10/22/2026 at 17:45, 4 hours 45 minutes ago

Third-quarter 2026 : Accor upgrades its EBITDA guidance

View all LES ECHOS COMFI WIRE